BlackRock, Inc. 13D and 13G filings for Intra-Cellular Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Intra-Cellular Therapies, Inc. ITCI |
BLACKROCK INC BLK |
6,218,671 5.900% |
0 (Unchanged) |
Filing |
| 2024-10-24 2:02 pm Sale |
2024-09-30 | 13G | Intra-Cellular Therapies, Inc. ITCI |
BLACKROCK INC BLK |
6,218,671 5.900% |
-1,974,316 (-24.10%) |
Filing |
| 2024-01-25 1:48 pm Purchase |
2023-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI |
BLACKROCK INC BLK |
8,192,987 8.500% |
743,458 (+9.98%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI |
BLACKROCK INC BLK |
7,449,529 7.900% |
1,727,763 (+30.20%) |
Filing |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI |
BLACKROCK INC BLK |
5,721,766 7.000% |
-176,802 (-3.00%) |
Filing |
| 2021-01-29 09:57 am Purchase |
2020-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI |
BLACKROCK INC BLK |
5,898,568 7.400% |
1,988,057 (+50.84%) |
Filing |